| scholarly article | Q13442814 |
| P50 | author | Alice L. Rodriguez | Q67215392 |
| Craig W. Lindsley | Q67215429 | ||
| P. Jeffrey Conn | Q67215432 | ||
| P2093 | author name string | Sameer Sharma | |
| P2860 | cites work | Application of combinatorial chemistry science on modern drug discovery | Q37065188 |
| A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators | Q40374968 | ||
| 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity | Q44958079 | ||
| Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity | Q28263355 | ||
| 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist | Q28374719 | ||
| Pharmacology and functions of metabotropic glutamate receptors | Q29619150 | ||
| Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo | Q30842826 | ||
| Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). | Q33223813 | ||
| Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. | Q33268568 | ||
| Pharmacological agents acting at subtypes of metabotropic glutamate receptors | Q33756933 | ||
| A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. | Q34222874 | ||
| A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain | Q34293120 | ||
| A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models | Q34377770 | ||
| Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes | Q34530165 | ||
| Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. | Q34564332 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lead | Q708 |
| pharmacology | Q128406 | ||
| P304 | page(s) | 4098-4101 | |
| P577 | publication date | 2008-05-29 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry Letters | Q2709483 |
| P1476 | title | Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold | |
| P478 | volume | 18 |
| Q37845809 | "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology |
| Q30464619 | (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction |
| Q34243209 | 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites |
| Q34001216 | 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats |
| Q30406728 | A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors |
| Q36717066 | A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling |
| Q38139547 | Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders |
| Q35952381 | Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery |
| Q35188110 | Allosteric modulation of the M₃ muscarinic receptor by amiodarone and N-ethylamiodarone: application of the four-ligand allosteric two-state model |
| Q37220392 | Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks |
| Q97595098 | Allosteric molecular switches in metabotropic glutamate receptors |
| Q38082089 | Approaches for probing allosteric interactions at 7 transmembrane spanning receptors |
| Q91822932 | Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68) |
| Q39346114 | Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. |
| Q39783930 | Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. |
| Q41820126 | Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold |
| Q38539247 | Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype |
| Q41985097 | Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors |
| Q34135392 | Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound |
| Q41891138 | Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety |
| Q30479035 | Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology |
| Q38687186 | Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines |
| Q38551529 | Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists |
| Q30472643 | Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity |
| Q24605838 | Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor |
| Q27006721 | Drugs for allosteric sites on receptors |
| Q30481884 | Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening |
| Q91581400 | Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology |
| Q38162957 | Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012). |
| Q30435534 | N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats |
| Q34399823 | Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders |
| Q38956226 | Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands |
| Q37183072 | Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors |
| Q36015452 | Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). |
| Q38774127 | Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1. |
| Q35210746 | Recent advances in the design and development of novel negative allosteric modulators of mGlu(5) |
| Q43193327 | Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants |
| Q33856038 | Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5 |
| Q30432649 | Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction |
| Q24605472 | Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders |
| Q33373225 | Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen |
| Q33370832 | Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties |
| Q41136066 | Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold |
| Q38539175 | Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS |
| Q41469232 | Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu(2)/mGlu(3) NAMs |
| Q24626912 | Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 |
| Q50877969 | Triple-addition assay protocols for detecting and characterizing modulators of seven-transmembrane receptors. |
Search more.